Results 241 to 250 of about 126,534 (277)

The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe? [PDF]

Biomolecules
Kounatidis D, Vallianou NG, Rebelos E, Vallianou K, Diakoumopoulou E, Makrilakis K, Tentolouris N.   +6 more
europepmc   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists Versus Bariatric Surgery in Patients With Obesity and Heart Failure With Preserved Ejection Fraction. [PDF]

J Am Heart Assoc
Ibrahim R, Han W, Wang W, Kau E, Said N, Forst B, Pham HN, Abdelnabi M, Salih M, Ali NB, Farina J, Lester SJ, Lee K, Ayoub C, Arsanjani R.   +14 more
europepmc   +1 more source

Emerging Role of Myostatin Inhibitors in the Management of Glucagon-Like Peptide-1-Associated Sarcopenia and Metabolic Disorders. [PDF]

J Bone Metab
Baik J, Lee YS.
europepmc   +1 more source

Association of glucagon-like peptide-1 receptor agonists with risk of gastrointestinal adverse events: evidence from a drug target Mendelian randomization. [PDF]

Eur Heart J Cardiovasc Pharmacother
Huang H, Liu J, Lu X, Tan N, Liu Y.
europepmc   +1 more source

Semaglutide and cardiovascular risk in type 1 diabetes: A predictive modelling analysis in a double‐blind, randomised, placebo‐controlled cross‐over trial

Diabetes, Obesity and Metabolism, EarlyView.
Luxcia Kugathasan, Michael A. Tsoukas, Massimo Nardone, Vikas S. Sridhar, Marcel H. A. Muskiet, David Z. I. Cherney, Ahmad Haidar, Melissa‐Rosina Pasqua   +7 more
wiley   +1 more source